Saturday 17 October 2026
Export MNTRQ’s income statement to Excel — free account
9 Meters Biopharma, Inc.
MNTRQ Healthcare Biotechnology
Follow MNTRQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 15 | 5 | 8 | 8 | 12 | 21 | 10 | ||||
| Revenue/emp, $m | — | — | — | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 4 | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 18.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EBT | — | — | — | (6) | (12) | (24) | (27) | (61) | (37) | (44) | |||||
| EBT margin, % | — | — | — | (152.79) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | (6) | (12) | (24) | (27) | (61) | (37) | (44) | |||||
| Depreciation | — | — | — | 2 | 0 | 3 | 1 | 2 | 0 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 147.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (224.00) | (19.53) | (19.60) | (15.60) | (11.60) | (3.00) | (3.38) | |||||
| Cash flow | — | — | — | (305.33) | (8.57) | (12.25) | (10.78) | (3.67) | (2.43) | (2.87) | |||||
| Capex | — | — | — | 0.00 | (0.07) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (305.33) | (8.64) | (12.26) | (10.79) | (3.68) | (2.43) | (2.87) | |||||
| Book value | — | — | — | 90.14 | (20.48) | (2.96) | (5.77) | 6.09 | 3.42 | 0.19 | |||||
| Shares, m | — | — | — | 0 | 1 | 1 | 2 | 5 | 12 | 13 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | — | — | — | — | — | — | ||||
| P/S | — | — | — | 2.38 | — | — | — | — | — | — | |||||
| P/B | — | — | — | 3.88 | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | 2.10 | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | (1.01) | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (8) | (5) | (15) | (18) | (19) | (29) | (37) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (8) | (5) | (15) | (18) | (19) | (29) | (37) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (12) | (4) | (10) | 32 | 42 | 2 | ||||
| Total debt | — | — | — | 0 | 9 | 5 | 3 | 0 | 0 | 20 | |||||
| Net debt | — | — | — | (1) | 0 | (6) | (5) | (38) | (47) | (13) | |||||
| Shareholders’ equity | — | — | — | 2 | (12) | (4) | (10) | 32 | 42 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (111.13) | (319.61) | (666.30) | (460.37) | (276.67) | (82.34) | (105.05) | ||||
| ROIC | — | — | — | (358.88) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 387.59 | 239.63 | 305.20 | 407.57 | (545.95) | (99.75) | (198.92) | |||||
Negative figures in brackets.
Fiscal years to Dec 2016 · latest quarter Dec 2016
Charts ten years each
9 Meters Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PTIX Atrinsic Inc. | $1.3M | 0.3× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRC SciSparc Ltd. | $1.2M | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +85.35% (above 0%: growing) | (157.79%) | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | −12.97% (below 0%: shrinking) | — | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LYRA Lyra Therapeutics, Inc. | $870.0K | — (loss-making) | — (loss-making) | −96.65% (below 0%: shrinking) | n/m | +45.44% (above 0%: growing) | 100.00% | (101,685.71%) | Compare |
| Median of peers | $1.1M | — | — | −65.98% | — | +45.76% | 0.00% | 0.00% |
9 Meters Biopharma, Inc. (MNTRQ) Latest News
No news at this impact. Lower the threshold for more.